Last reviewed 2026-04-23 · How we verify

estradiol (Zesteem)

Renovo · Phase 3 active Small molecule

estradiol (Zesteem) is a estrogen receptor agonist Small molecule drug developed by Renovo. It is currently in Phase 3 development for Treatment of menopausal symptoms, including hot flashes and vaginal dryness, Prevention of osteoporosis in postmenopausal women.

Estradiol acts as an estrogen receptor agonist, mimicking the effects of the naturally occurring hormone estrogen in the body.

Estradiol acts as an estrogen receptor agonist, mimicking the effects of the naturally occurring hormone estrogen in the body. Used for Treatment of menopausal symptoms, including hot flashes and vaginal dryness, Prevention of osteoporosis in postmenopausal women.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	estradiol (Zesteem)
Sponsor	Renovo
Drug class	estrogen receptor agonist
Target	estrogen receptor
Modality	Small molecule
Therapeutic area	Women's Health
Phase	Phase 3

Mechanism of action

Estradiol binds to estrogen receptors in various tissues, including the uterus, breast, and bone, leading to changes in gene expression and cellular behavior. This results in a range of physiological effects, including the regulation of the menstrual cycle, the maintenance of bone density, and the modulation of lipid metabolism.

Approved indications

Treatment of menopausal symptoms, including hot flashes and vaginal dryness
Prevention of osteoporosis in postmenopausal women

Common side effects

Vaginal bleeding
Breast tenderness
Headache
Nausea

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

estradiol (Zesteem) CI brief — competitive landscape report
estradiol (Zesteem) updates RSS · CI watch RSS
Renovo portfolio CI

Frequently asked questions about estradiol (Zesteem)

What is estradiol (Zesteem)?

estradiol (Zesteem) is a estrogen receptor agonist drug developed by Renovo, indicated for Treatment of menopausal symptoms, including hot flashes and vaginal dryness, Prevention of osteoporosis in postmenopausal women.

How does estradiol (Zesteem) work?

Estradiol acts as an estrogen receptor agonist, mimicking the effects of the naturally occurring hormone estrogen in the body.

What is estradiol (Zesteem) used for?

estradiol (Zesteem) is indicated for Treatment of menopausal symptoms, including hot flashes and vaginal dryness, Prevention of osteoporosis in postmenopausal women.

Who makes estradiol (Zesteem)?

estradiol (Zesteem) is developed by Renovo (see full Renovo pipeline at /company/renovo).

What drug class is estradiol (Zesteem) in?

estradiol (Zesteem) belongs to the estrogen receptor agonist class. See all estrogen receptor agonist drugs at /class/estrogen-receptor-agonist.

What development phase is estradiol (Zesteem) in?

estradiol (Zesteem) is in Phase 3.

What are the side effects of estradiol (Zesteem)?

Common side effects of estradiol (Zesteem) include Vaginal bleeding, Breast tenderness, Headache, Nausea.

What does estradiol (Zesteem) target?

estradiol (Zesteem) targets estrogen receptor and is a estrogen receptor agonist.

Drug class: All estrogen receptor agonist drugs
Target: All drugs targeting estrogen receptor
Manufacturer: Renovo — full pipeline
Therapeutic area: All drugs in Women's Health
Indication: Drugs for Treatment of menopausal symptoms, including hot flashes and vaginal dryness
Indication: Drugs for Prevention of osteoporosis in postmenopausal women

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing